Reference

Immunochemical determination of drug-induced thrombocytopenia

Immunochemical determination of drug-induced thrombocytopenia.Some chemicals with cas registry numbers like 9045-22-1 and 56-54-2 are also used. Amiral, Jean (Serbio, Fr.). PCT Int. Appl. WO 9202823 A1 20 Feb 1992, 46 pp. DESIGNATED STATES: W: JP, US; RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE. (World Intellectual Property Organization). CODEN: PIXXD2. CLASS: ICM: G01N033-94. ICS: G01N033-86; G01N033-569; G01N033-50; G01N033-564. APPLICATION: WO 91-FR659 9 Aug 1991. PRIORITY: FR 90-10190 9 Aug 1990. DOCUMENT TYPE: Patent CA Section: 9 (Biochemical Methods) Section cross-reference(s): 4, 15 A method is disclosed for detn. of thrombocytopenia induced by drugs (e.g. heparin or quinine/quinidine). The detn. uses an antigenic substance chosen from fractions which (1) are present in blood platelets and freed therefrom by lysis and (2) have a strong affinity for the inducing drug and/or complexes of the inducing drug with the platelets; the antigenic substance is intended to react with an anti-inducer drug (or fragments thereof or products/fragments contg. it) antibody contained in the blood plasma to be tested. In the detn. of heparin-induced thrombocytopenia, the antigenic substance is, e.g., platelet factor 4. A kit for performing the method is also disclosed. An immunoassay protocol is described which was used to test for heparin-induced thrombocytopenia in patient plasma samples in comparison with a prior-art method using heparin-induced platelet agglutination. .

Innotrac Aio!: a point-of-care or a routine analyzer? Analytical performance and plasma/whole blood comparison

All Rights Reserved. Innotrac Aio!: a point-of-care or a routine analyzer? Analytical performance and plasma/whole blood comparison.Some chemicals with cas registry numbers like 9001-15-4 and 9045-22-1 are also used. Altinier, Sara; Zaninotto, Martina; Mion, Monica Maria; Plebani, Mario ( Department of Laboratory Medicine, University-Hospital of Padova, Padua, Italy). Clinical Chemistry and Laboratory Medicine, 44(10), 1278-1282 (English) 2006 Walter de Gruyter GmbH & Co. KG. CODEN: CCLMFW. ISSN: 1434-6621. DOCUMENT TYPE: Journal CA Section: 9 (Biochemical Methods) The aim of the present study was to evaluate the anal. performance of the Innotrac Aio! analyzer in measuring the cardiac markers troponin I (TnI), myoglobin (Myo) and creatine kinase-MB (CK-MB), both in lithium heparin plasma and in whole blood. Results: TnI anal. sensitivity was 0.012 mg/L and the concn. corresponding to CV = 10% was 0.036 mg/L. In healthy subjects, the 99th percentile TnI values were 0.023 and 0.016 mg/L in whole blood and in plasma resp. One hundred samples were tested both in whole blood and in plasma: TnI-whole-blood = 1.16-plasma +0.011, bias = +0.18 (95% Cl from -0.22 to +0.59); Myo-whole-blood = 1.04-plasma-1.93, bias = +1.08 (95% Cl from -6.17 to +8.32); CK-MB-whole-blood = 1.11-plasma-0.09, bias = +0.96 (95% Cl from -0.53 to +2.45). The method comparison with the RxL Dimension analyzer for TnI and Myo gave the following results: TnI Aio! = 0.30 TnI RxL +0.00; bias = -5.80 (95% Cl from -7.81 to -3.78), Myo Aio! = 1.33 Myo RxL +0.42, bias = +53.09 (95% Cl from +38.44 to +67.74). Conclusions: The anal. performance of the Innotrac Aio! analyzer was satisfactory for all three cardiac markers evaluated and, in particular, the TnI method provided sensitive and accurate results. The most important finding in this study is the possibility to perform the tests as either routine or point-of-care anal., thus overcoming the variability of results obtained employing different methods. .